 Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study of its leukemia treatment. The stock skyrocketed 256.3, putting them on track to open at the highest price seen during regular-session hours since March 2018. 